‘Celebrex’ developed the most for bioequivalently approved generics last year
A pharmaceutical product which was developed as generics by the most number of pharmaceutical companies was ‘Celebrex’ last year.
According to the Medipana News’ analysis result of the Ministry of Food and Drug Safety’s official announcement for bioequivalence approvals on the 1st, there were th...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
